Stocks in play: Oncolytics Biotech Inc.

Announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15 , 2021. In the poster, data from the twenty HR+/HER2- early-stage breast cancer patients included in AWARE-1's first two cohorts are presented. These patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) the PD-L1 inhibitor atezolizumab (Tecentriq ®) prior to surgery. Evaluation of cohorts 1 and 2 is the core objective of AWARE-1, as HR+/HER2- is the breast cancer subtype Oncolytics intends to examine in a future registrational study. Oncolytics Biotech Inc. shares T.ONC are trading unchanged at $4.99.

Read:

• Mainstream Mental Health is Quickly Embracing Psychedelic Drug Therapies

• Matsuyama Makes History with Green Jacket at Augusta; DraftKings and DGTL Winners at Masters Too